公开(公告)号：US20200338180A1

公开(公告)日：2020-10-29

申请号：US16333596

申请日：2017-09-15

申请人： Infectious Disease Research Institute

发明人： Steven G. REED ,  Malcolm S. Duthie

IPC分类号： A61K39/04 ,  A61K39/39

摘要： Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.

公开(公告)号：US09907845B2

公开(公告)日：2018-03-06

申请号：US14096582

申请日：2013-12-04

申请人： Infectious Disease Research Institute

发明人： Steven G. Reed ,  Darrick Carter

IPC分类号： A61K39/395 ,  A61K39/39 ,  A61K9/107 ,  A61K39/00 ,  A61K39/35 ,  A61K45/06 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145

CPC分类号： A61K39/39 ,  A61K9/107 ,  A61K39/0011 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145 ,  A61K39/35 ,  A61K45/06 ,  A61K2039/55511 ,  A61K2039/55572 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/41 ,  Y02A50/491

摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20150182612A1

公开(公告)日：2015-07-02

申请号：US14419477

申请日：2013-08-02

申请人： Infectious Disease Research Institute

发明人： Steven G. Reed ,  Rhea N. Coler

IPC分类号： A61K39/04 ,  A61K39/39 ,  A61K45/06

CPC分类号： A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/70 ,  A61K2300/00

摘要： The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.

摘要翻译： 本公开涉及用于治疗活动性结核感染的方法和组合物，以及用于改善针对活动性结核感染的化疗方案的功效的方法和组合物。 本公开涉及治疗活动性结核分枝杆菌感染或由哺乳动物的潜伏感染的再活化引起的活性感染的方法以及提高针对活动性结核分枝杆菌感染的化学疗法疗效的方法。

公开(公告)号：US20150017200A1

公开(公告)日：2015-01-15

申请号：US14286647

申请日：2014-05-23

申请人： INFECTIOUS DISEASE RESEARCH INSTITUTE

发明人： Ajay BHATIA ,  Steven G. REED

IPC分类号： C07K14/44 ,  G01N33/569 ,  C07K16/20

CPC分类号： C07K14/44 ,  A61K38/00 ,  A61K39/00 ,  C07K16/20 ,  G01N33/56905 ,  G01N33/6893 ,  Y10S435/81 ,  Y10S435/975

摘要： The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.

摘要翻译： 本发明一般涉及由包含源自利什曼原虫抗原K26，K39和K9的元件的合成基因构建体制成的融合蛋白。 融合蛋白特别可用于诊断利什曼病，特别是动物如人和狗中的内脏利什曼病。

公开(公告)号：US08911746B2

公开(公告)日：2014-12-16

申请号：US13794903

申请日：2013-03-12

申请人： Yasuyuki Goto ,  Steven G. Reed

发明人： Yasuyuki Goto ,  Steven G. Reed

IPC分类号： A61K39/008 ,  C12N15/62 ,  C07K14/44 ,  A61K39/00

CPC分类号： A61K39/008 ,  A61K2039/552 ,  A61K2039/55572 ,  C07K14/44 ,  C12N15/62

摘要： Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.

摘要翻译： 公开了用于预防，治疗和检测利什曼病的组合物和方法。 组合物通常包含包含多个利什曼原虫抗原，特别是KMP11，SMT，A2和/或CBP或其免疫原性部分或变体，以及编码这种融合多肽的多核苷酸的融合多肽。

公开(公告)号：US20140037691A1

公开(公告)日：2014-02-06

申请号：US13930953

申请日：2013-06-28

申请人： Steven G. Reed ,  Darrick Carter

发明人： Steven G. Reed ,  Darrick Carter

IPC分类号： A61K39/39 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K9/107 ,  A61K39/0011 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145 ,  A61K39/35 ,  A61K45/06 ,  A61K2039/55511 ,  A61K2039/55572 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/41 ,  Y02A50/491

摘要： Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20130345079A1

公开(公告)日：2013-12-26

申请号：US13880025

申请日：2011-08-16

申请人： Gregory C. Ireton ,  Steven G. Reed

发明人： Gregory C. Ireton ,  Steven G. Reed

IPC分类号： G01N33/569

CPC分类号： G01N33/5695 ,  C07K14/35 ,  C07K2319/00

摘要： The present invention relates to compositions and fusion proteins containing comprising Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the diagnosis, treatment and/or prevention of tuberculosis infection.

摘要翻译： 本发明涉及包含分枝杆菌属（Mycobacterium sp。）的组合物和融合蛋白。 抗原和编码这种组合物的多核苷酸和融合蛋白。 本发明还涉及其用于诊断，治疗和/或预防结核病感染的方法。

公开(公告)号：US08470338B2

公开(公告)日：2013-06-25

申请号：US11912730

申请日：2006-04-27

申请人： Rhea Coler ,  Yves Lobet ,  Steven Reed

发明人： Rhea Coler ,  Yves Lobet ,  Steven Reed

IPC分类号： A61K39/04 ,  A61K49/00 ,  A61K39/02

CPC分类号： A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  C07K14/35

摘要： The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

公开(公告)号：US08425919B2

公开(公告)日：2013-04-23

申请号：US12466580

申请日：2009-05-15

申请人： Yasuyuki Goto ,  Steven G. Reed

发明人： Yasuyuki Goto ,  Steven G. Reed

IPC分类号： A61K39/008 ,  C07H21/04

CPC分类号： C07K14/44 ,  A61K39/008 ,  C12N15/62 ,  Y02A50/41

摘要： Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.

公开(公告)号：US20120114688A1

公开(公告)日：2012-05-10

申请号：US13290834

申请日：2011-11-07

申请人： Ajay Bhatia ,  Steven G. Reed

发明人： Ajay Bhatia ,  Steven G. Reed

IPC分类号： A61K39/008 ,  C12N15/62 ,  A61P33/02 ,  C12N11/00 ,  A61P37/04 ,  C12N9/10 ,  G01N33/569

CPC分类号： C12N9/1007 ,  A61K39/008 ,  C07K14/44 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/41 ,  C12N9/2497 ,  Y02A50/41

摘要： Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising Leishmania antigens, in particular, SMT and NH antigens or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.

摘要翻译： 公开了用于预防，治疗和检测利什曼病的组合物和方法。 组合物通常包含包含利什曼原虫抗原，特别是SMT和NH抗原或其免疫原性部分或变体的融合多肽，以及编码这种融合多肽的多核苷酸。